Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

Ulrike Klein MD; Anna Jauch PhD; Thomas Hielscher; Jens Hillengass MD; Marc S. Raab MD; Anja Seckinger MD; Dirk Hose MD; Anthony D. Ho MD; Hartmut Goldschmidt MD; Kai Neben MD

首页> 外文期刊>Cancer >Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

【24h】

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

机译：来那度胺和地塞米松治疗的复发性多发性骨髓瘤患者的染色体畸变+ 1q21和del（17p13）预测存活率

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM).

机译：在来那度胺和硼替佐米等新型药物时代，由于染色体异常引起的危险分层可能使多发性骨髓瘤（MM）患者的治疗方法更加合理。

著录项

来源
《Cancer》 |2011年第10期|2136-2144|共9页
作者
Ulrike Klein MD; Anna Jauch PhD; Thomas Hielscher; Jens Hillengass MD; Marc S. Raab MD; Anja Seckinger MD; Dirk Hose MD; Anthony D. Ho MD; Hartmut Goldschmidt MD; Kai Neben MD;
展开▼
作者单位

Department of Internal Medicine V University of Heidelberg Heidelberg Germany;

Institute for Human Genetics University of Heidelberg Heidelberg Germany;

Department of Biostatistics German Cancer Research Center Heidelberg Germany;

National Center for Tumor Diseases Heidelberg Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
multiple myeloma; lenalidomide; cytogenetics; overall survival;

机译：多发性骨髓瘤;来那度胺;细胞遗传学;总生存;

相似文献

外文文献
中文文献
专利

1. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. [J] . Klein U, Jauch A, Hielscher T, Cancer: A Journal of the American Cancer Society . 2011,第10期

机译：来那度胺和地塞米松治疗的复发性多发性骨髓瘤患者的染色体畸变+ 1q21和del（17p13）预测存活率。
2. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. [J] . Chang H, Jiang A, Qi C, Leukemia and lymphoma . 2010,第11期

机译：来那度胺和地塞米松治疗的复发或难治性多发性骨髓瘤患者，包括1号染色体异常在内的基因组畸变的影响。
3. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. [J] . San Miguel JF, Dimopoulos MA, Stadtmauer EA, Clinical lymphoma, myeloma & leukemia . 2011,第1期

机译：来那度胺和地塞米松治疗持续时间对来那度胺和地塞米松治疗的复发或难治性多发性骨髓瘤患者生存率的影响。
4. Hedge Algebra Based Type-2 Fuzzy Logic System and its Application to Predict Survival Time of Myeloma Patients [C] . Phong Phan Anh, Dong Dinh Khac, Khang Tran Dinh Knowledge and Systems Engineering, 2009. KSE '09 . 2009

机译：基于对冲代数的2型模糊逻辑系统及其在骨髓瘤患者生存时间预测中的应用
5. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study [O] . Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, 2018

机译：在III期ASPIRE研究中使用卡非佐米来那度胺和地塞米松（KRd）与来那度胺和地塞米松（Rd）治疗的复发性多发性骨髓瘤患者根据计划的治疗持续时间无应答和无进展生存
6. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone [O] . Ulrike Klein, Anna Jauch, Thomas Hielscher, 2010

机译：染色体像差+ 1Q21和Del（17P13）预测用Lenalidomide和地塞米松治疗复发多发性骨髓瘤患者的存活

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅